In a patient with a history of gastroesophageal reflux disease and no cardiac disease, presenting with epigastric pain, a negative CT scan, normal troponin, normal lipase, and no other laboratory abnormalities, what is the likely diagnosis?

Functional Dyspepsia (Likely Epigastric Pain Syndrome)

Your patient most likely has functional dyspepsia (FD), specifically epigastric pain syndrome (EPS), given the history of GERD, epigastric pain presentation, and negative workup excluding structural, cardiac, and pancreatic pathology 1.

Diagnostic Reasoning

With normal troponin (cardiac cause excluded), normal lipase (pancreatitis excluded), negative CT (structural pathology excluded), and no laboratory abnormalities, you've effectively ruled out organic disease. In patients with dyspepsia symptoms and negative investigations, 80% will be diagnosed with functional dyspepsia 1.

Classification of Your Patient's Presentation

The epigastric pain pattern suggests Epigastric Pain Syndrome (EPS), one of two FD subtypes defined by Rome criteria 1:

• EPS: Epigastric pain or burning occurring at least once per week, often present regardless of meals
• PDS (Postprandial Distress Syndrome): Early satiation and postprandial fullness triggered by meals, occurring three times per week

Your patient's presentation aligns with EPS given the epigastric pain focus without mention of meal-related fullness or early satiation.

Critical Next Steps

1. Test for H. pylori Immediately

All patients with FD should receive stool antigen or breath testing for H. pylori 1. If positive, provide eradication therapy with antibiotics—this may resolve symptoms entirely.

2. Initial Treatment Approach

For patients testing H. pylori negative (or remaining symptomatic after eradication):

Start a 4-8 week trial of single-dose PPI therapy 2. Given the GERD history, this patient may already be on PPIs, but ensure adequate dosing (e.g., omeprazole 20mg once daily) 3.

• If inadequate response: escalate to twice-daily dosing 2
• After symptom control: titrate to lowest effective dose 2, 3

3. If PPI Therapy Fails

Consider these evidence-based options in sequence 1:

• Tricyclic antidepressants (TCAs): Work on pain modulation and gut-brain axis
• Prokinetic agents: If gastroparesis-like symptoms emerge
• Neuromodulators: SNRIs or mirtazapine for refractory cases

Common Pitfalls to Avoid

Do not assume this is "just GERD" despite the history. While GERD and FD frequently coexist, the negative workup and epigastric pain pattern suggest FD as the primary driver. The Rome Foundation acknowledges that heartburn alone is not a symptom of dyspepsia, although it can coexist 1.

Do not over-restrict diet without evidence. While some patients benefit from avoiding trigger foods, there is no evidence for specialized diets in treating FD, and excessive restriction risks malnutrition 1.

Vomiting would be atypical—if present, reconsider the diagnosis and investigate for other disorders 1.

Underlying Pathophysiology

FD results from disrupted gut-brain communication 1:

• Visceral hypersensitivity (nerves making the stomach/duodenum more sensitive)
• Delayed gastric emptying (contributing to fullness)
• Psychological factors (stress, anxiety)
• Possible alterations in gut microbiota

Normal test results do not mean there is no cause—the pathology exists at the functional level, not structural 1.

Long-term Management Considerations

Encourage lifestyle modifications including regular exercise and stress management 1. Provide patient education about the gut-brain axis and the chronic, relapsing nature of FD 2.

If symptoms persist despite H. pylori treatment and PPI optimization, consider referral for behavioral interventions like cognitive behavioral therapy (CBT), which has demonstrated efficacy in FD 1.